Seguimento de 5 anos de acuidade visual de pacientes com degeneração macular relacionada à idade exudativa (ÚMIDA) tratada com radioterapia e medicamentos antiangiogênicos / 5 years follow-up of visual acuity from patients with exudative (WET) age-related macular degeneration, treated with radiotherapy and antiangiogenic drugs

Lívia Carla de Souza Nassar Bianchi, Lorena Tassara Quirino Vieira, David Leonardo Cruvinel Isaac, Marcos Pereira de Ávila

Abstract


Objetivo: a degeneração macular relacionada à idade (DMRI) é atualmente uma das principais causas de deficiência visual grave em pacientes com mais de 55 anos. Existem aproximadamente 170 milhões de pessoas com alguma forma da doença em todo o mundo. Os tratamentos atuais da forma exsudativa ainda apresentam limitações, principalmente relacionadas à necessidade de inúmeras injeções intravítreas de antiangiogênicos ao longo do seguimento. O objetivo deste estudo é avaliar a acuidade visual e estabilidade de pacientes tratados com radioterapia intraocular com estrôncio 90 e duas injeções intravítreas de bevacizumabe nos 16 pacientes do grupo I, e uma aplicação de radioterapia intraocular com estrôncio 90 e duas injeções intravítreas de ranibizumabe em 13 pacientes no grupo II durante um acompanhamento de 5 anos.

Métodos: Todos os 29 pacientes apresentaram neovascularização de coróide secundária à DMRI e foram acompanhados com exame oftalmológico completo, angiografia de fluorescência e tomografia de coerência óptica.

Resultados: 87,5% dos pacientes do grupo I e 53,84% do grupo II mantiveram boa acuidade visual ao final dos 60 meses de seguimento. A média da melhor acuidade visual corrigida apresentou ganho de + 10,4 letras e + 5,23 letras, respectivamente, em tabela específica. O grupo bevacizumabe manteve-se estável ao longo do acompanhamento, além de um maior número de pacientes que alcançou acuidade visual ≥ 20/40.

Conclusão: A radioterapia intraocular combinada com antiangiogênicos se enquadra no arsenal terapêutico disponível para DMRI neovascular como uma opção segura, especialmente nos casos que ocorrem com injeções intravítreas repetidas.

 


Keywords


degeneração macular, neovascularização coroidal, braquiterapia, estrôncio 90, antiangiogênico, bevacizumabe, ranibizumabe.

References


ABECASIS G. R.; YASHAR B. M.; ZHAO Y.; GHIASVAND N. M.; ZAREPARSI S.; BRANHAM K. E.; BRANHAM K. E.; REDDICK A. C.; TRAGER E. H.; YOSHIDA S.; BAHLING J.; FILIPPOVA E.; ELNER S.; JOHNSON M. W.; VINE A. K.; SIEVING P. A.; JACOBSON S. G.; RICHARDS J. E.; SWAROOP A. Age-related macular degeneration: a high-resolution genome scan for susceptibility loci in a population enriched for late-stage disease. American Journal of Human Genetics, v. 74, p. 482-94, 2004.

ABEDI F.; WICKREMASINGHE S.; ISLAM A.F. et al. Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years. Retina. 34:1531–1538; 2014.

ABRAHAM P.; YUE H.; WILSON L. et al. Randomized, double-masked, shamcontrolled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study Year 2. Am J Ophthalmol. 150: 315–324, 2010.

ADAMIS, A.P.; MILLER J.W.; BERNAL M.T.; D'AMICO D.J.; FOLKMAN J.; YEO T.K.; YEO, K.T. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 118(4): 445-450, 1994.

AGE-RELATED EYE DISEASE STUDY RESEARCH GROUP. A randomized, placebo-controlled, clinical trial of high dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. AREDS report number 8. Archives of Ophthalmology, v.119, p. 1417–36, 2001.

AHN J.; KIM H.; WOO S.J.; PARK J.H.; PARK S.; HWANG D.J.; PARK K.H. Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes. J Ocul Pharmacol Ther. Sep;29(7):612-8, 2013.

AHN S.J.; AHN J.; PARK S.; KIM H.; HWANG D.J.; PARK J.H.; PARK J.Y.; CHUNG J.Y.; PARK K.H.; WOO S.J. Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes. Invest Ophthalmol Vis Sci. Jan 29;55(1):567-73, 2014.

AIELLO, L.P.; AVERY, R.L.; ARRIGG P.G.; KEYT B.A.; JAMPEL H.D.; SHAH S.T.; PASQUALE L.R.; THIEME H.; IWAMOTO M.A.; PARK J.E. etal. Vascular endotelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 331(22):1480-1487,1994.

AIELLO L.P.; BRUCKER A.J.; CHANG S.; CUNNINGHAM E.T. JR.; D'AMICO D.J.; FLYNN H.W. JR.; et al. Evolving guidelines for intravitreous injections. Review. Retina, 24(Suppl 5): S3-19, 2004.

AMERI H.; CHADER G. J.; KIM J. G.; RAO N. A.; HUMAYUN M. S. The effects of intravitreous bevacizumab on retinal neovascular membrane and normal capillaries in rabbits. Investigative Ophthalmology & Visual Science, v.48, n.12, p.5708-5715, Dec. 2007.

ANTOSZYK A.N.; TUOMI L.; CHUNG C.Y.; et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration. Am J Ophthalmol. 145: 862–874, 2008. AREVALO J. F.; FROMOW-GUERRA J.; SANCHEZ J. G.; MAIA M.; BERROCAL M. H.; WU L.; SARAVIA M. J.; COSTA R. A. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Retina, v. 28, p.1387-1394, 2008. ARCHAMBEAU J.O.; MAO X.W.; YONEMOTO L.T.; et al. What is the role of radiation in the treatment of subfoveal membranes: review of radiobiologic, pathologic, and other considerations to initiate a multimodality discussion. Int J Radiat Oncol Biol Phys. 40(5):1125–1136, 1998.

ARMBRECHT A. M.; ASPINALL P. A.; DHILLON B. A prospective study of visual function and quality of life following PDT in patients with wet age related macular degeneration. British Journal of Ophthalmology, v. 88, p.1270-1273, 2004.

AUGUSTIN A. J.; SCHMIDT-ERFURTH, U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. American Journal of Ophthalmology, v. 141, p. 638-645, 2006.

ÁVILA M.P.; TALEB A.C.; GONÇALVES J.O.R.; et al. Degeneração macular relacionada à idade. Retina e Vítreo, Clínica e Cirurgia. Ed. Roca, São Paulo, 1:433- 451, 2000.

ÁVILA M. P.; FARAH M.; ISAAC D. L. C. Combined Photodynamic Therapy with Verteporfin and Intravitreal Triamcinolone Acetonide for Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration. ASRS Meeting, Montreal 2005.

ÁVILA M. P.; FARAH M. E.; SANTOS A.; KAPRAN Z.; DUPRAT J. P.; WOODWARD B. W.; NAU, J. Twelve-month safety and visual acuity results from a feasibility study of intraocular, epiretinal radiation therapy for the treatment of subfoveal CNV secondary to AMD. Retina, v. 29, p. 157–69, 2009a.

ÁVILA M.P.; FARAH M.E.; SANTOS A.; KAPRAN Z.; DUPRAT J. P.; WOODWARD B. W.; NAU, J. Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal stron-tium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration. British Journal of Ophthalmology, v. 93, p. 305-9, 2009b.

ÁVILA M. P.; FARAH M. E.; SANTOS A.; CARLA L.; FUJI G.; ROSSI J.; NAU J. Three-Year safety and visual acuity results of epimacular 90strontium/90yttrium brachytherapy with Bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Retina. 32(1): 10– 18, 2012.

BASHSHUR Z. F.; HADDAD Z. A.; SCHAKAL A.; JAAFAR R. F.; SAAB M.; NOUREDDIN B. N. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. American Journal of Ophthalmology, v. 145, p.249-256, 2008.

BEATTY S.; KOH H.; PHIL M.; HENSON D.; BOULTON M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Survey of Ophthalmology, v. 45, p.115-134, 2000. BELTRAN W. A. On the role of CNTF as a potential therapy for retinal degeneration: Dr. Jekyll or Mr. Hyde? Advances in Experimental Medicine and Biology Journal, v. 613, p. 45-51, 2008.

BENJAMIN, L.E.; HEMO I.; KESHET E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development., v. 125, n. 9, p. 1591- 1598. 1998.

BERG K.; PEDERSON T.R.; SANDVIK L.; BRAGADOTTIR R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 122: 146–52, 2015.

BERG K.; HADZALIC E.; GJERTSEN I.; et al. Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the Lucentis compared to Avastin study treat-and-extend protocol: Two-year results. Ophthalmology. 123: 51–9, 2016. BERGINK G. J.; HOYNG C. B.; VAN DER MAAZEN R. W.; VINGERLING J. R.; VAN DAAL W. A.;

DEUTMAN A. F. A randomized controlled clinical trial on the efficacy of radiation therapy in the control of subfoveal choroidal neovascularization in age-related macular degeneration: radiation versus observation. Graefe's Archive for Clinical and Experimental Ophthalmology, v. 236, p. 321-5, 1998.

BERGLIN L.; SARMAN S.; VAN DER PLOEG I.; STEEN B.; MING Y.; ITOHARA S.; SEREGARD S.; KVANTA A. Reduced choroidal neovascular membrane formation in matrix metalloproteinase-2-deficient mice. Investigative Ophthalmology & Visual Science, v. 44, p. 403-8, 2003.

BIRD A.; BRESSLER N. M.; BRESSLER S. B. An international classification and grading system for age-related maculopathy and age-related macular degeneration: The International ARM Epidemiological Study Group. Survey of Ophthalmology, v. 39, p. 367-74, 1995.

BISCHOFF P. M.; FLOWER R. W. Ten years experience with choroidal angiography using indocyanine green dye: a new routine examination or an epilogue? Documenta Ophthalmologica, v. 60, p.235-291, 1985.

BLINDER K. J.; BRADLEY S.; BRESSLER N. M.; BRESSLER S. B.; DONATI G.; HAO Y.; MENCHINI U.; MILLER J.; POTTER M. J.; POURNARAS C.; REAVES A.; ROSENFELD P. J.; STRONG H. A.; STUR M.; SU X. Y.; VIRGILI G. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report nº 1. American Journal of Ophthalmology, v. 136, p. 407-418, 2003.

BLOCH S.B.; LARSEN M.; MUNCH I.C. Incidence of legal blindness from agerelated macular degeneration in denmark: year 2000 to 2010. American Journal of Ophthalmology Feb;153(2): 209-213, 2012.

BOYER D.S.; HEIER J.S.; BROWN D.M.; et al. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 116: 1731–1739, 2009.

BRESSLER S. B.; BRESSLER N.; FINE S. L.; HILLIS A.; MURPHY R. P.; OLK R. J.; PATZ A. Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration. American Journal of Ophthalmology, v. 93, p.157-163, 1982.

BRESSLER N. M.; BRESSLER S. B.; GRAGOUDAS E. S. Clinical characteristics of choroidal neovascular membranes. Archives of Ophthalmology, v. 105, p. 209-13, 1987. BRESSLER N. M.; BRESSLER S. B.; FINE S. L. Age related macular degeneration. Survey of Ophthalmology, v. 32, p. 375-413, 1988.

BRESSLER S. B.; MAGUIRE M. G.; BRESSLER N. M.; FINE S. L. Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. Archives of Ophthalmology, v. 108, p.1442–7, 1990.

BRESSLER N. M.; MUNOZ B.; MAGUIRE M. G.; VITALE S. E.; SCHEIN O. D.; TAYLOR H. R.; WEST S. K. Five-year incidence and disappearance of drusen and retinal pigment epithelial abnormalities. Waterman study. Archives of Ophthalmology, v. 113, p. 301-308, 1995.

BRESSLER N.M. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report nº2. Archives of Ophthalmology, v. 119, p. 198-207, 2001a.

BRESSLER N. M.; HAWKINS B. S.; STERNBERG JR P.; MCDONALD H. R. Are the submacular surgery trials still relevant in an era of photodynamic therapy? Ophthalmology, v. 108, p. 435-436, 2001b. BRESSLER N.M. Age-related macular degeneration is the leading cause of blindness. JAMA. 291:1900–1901, 2004.

BRESSLER S. B.; PIERAMICI D. J.; KOESTER J. M.; BRESSLER N. M. Occult with no classic subfoveal choroidal neovascular lesions in age-related macular degeneration: clinically relevant natural history information in larger lesions with good vision from the Verteporfin in Photodynamic Therapy (VIP) Trial: VIP Report nº 4. Archives of Ophthalmology, v. 124, p. 660-664, 2006.

BRODY B. L.; GAMST A. C.; WILLIAMS R. A.; SMITH A. R.; LAU P. W.; DOLNAK D.; RAPAPORT M. H.; KAPLAN R. M.; BROWN S. I. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology, v.108, p.1893-1900, 2001. BROWN D. M.; KAISER P. K.; MICHELS M.; SOUBRANE G.; HEIER J. S.; KIM R. Y.; SY J. P.; SCHNEIDER S. Ranibizumab versus verteporfin for neovascular agerelated macular degeneration. New England Journal of Medicine, v. 355, p. 1432-44, 2006.

BROWN D. M.; REGILLO C. D.; ABRAHAM P.; YUE H.; IANCHULEV T.; SCHNEIDER S.; SHAMS N. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER STUDY year 1. American Journal of Ophthalmology, v.145, p. 239-48, 2008.

BROWN D. M.; MICHELS M.; KAISER P. K.; HEIER J. S.; SY J. P.; IANCHULEV T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology, v. 116, p. 57-65, 2009.

BRUNI L.F.; CRUZ A.A. Chromatic sense: types of defects and clinical evaluation tests. Arq Bras Oftalmol. Sep-Oct;69 (5) :766-75, 2006. CANTON V.M.; QUIROZ-MERCADO H.; VELEZ-MONTOYA R.; et al. 24-Gy lowvoltage X-ray irradiation with ranibizumab therapy for neovascular AMD: 6-month safety and functional outcomes. Ophthalmic Surg Lasers Imaging. 43(1): 20–24, 2012.

CASELLA A.M.B.; TABA K.E.; RAMOS A.; FARAH M.E. Indocianina verde vídeoangiografia e oftalmoscopia de rastreamento a laser em neovascularização subretiniana. Arq Bras Oftalmol. v. 61 n. 2, p. 230-2, 1998. CHAKRAVARTHY U.; HART P. External beam radiation therapy for CNV. Ophthalmology, v. 105, p. 1790-1791, 1988.

CHAKRAVARTHY U.; GARDINER T. A.; ARCHER D. B.; MAGUIRE C. J. A light microscopic and autoradiographic study of non-irradiated and irradiated ocular wounds. Current Eye Research, v.8, p. 337-48, 1989.

CHAKRAVARTHY U.; HOUSTON R. F.; ARCHER D. B. Treatment of age-related subfoveal neovascular membranes by teletherapy: a pilot study. British Journal of Ophthalmology, v. 77, p. 265-73, 1993.

CHAKRAVARTHY U.; HART P. Age-related macular disease: intervention possibilities. Community Eye Health, v.12, p. 9-10,1999 CHAKRAVARTHY U.; MACKENZIE G. External beam radiotherapy in exudative age-related macular degeneration: a pooled analysis of phase I data. Br J Radiol. Mar; 73(867): 305-13, 2000.

CHAKRAVARTHY U.; ADAMIS A. P.; CUNNINGHAM JR E. T.; GOLDBAUM M.; GUYER D. R.; KATZ B.; PATEL M. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology, v. 113, p. 1508 e 1-25, 2006.

CHAKRAVARTHY, U.; HARDING, S. P.; ROGERS, C. A.; DOWNES, S. M.; LOTERY, A. J. et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology, v. 119, n. 7, p. 1399-1411, July 2012.

CHAKRAVARTHY U.; HARDING S.P.; ROGERS C.A.; DOWNES S.M.; LOTERY A.J.; WORDSWORTH S.; REEVES B.C. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. Aug;119(8):1508, 2012. Ophthalmology. Sep;120(9):1719, 2013a.

CHAKRAVARTHY U.; HARDING S.P.; ROGERS C.A.; et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 382: 1258–67, 2013b.

CHAN W. M.; LAI T. Y.; WONG A. L.; TONG J. P.; LIU D. T.; LAM D. S. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. British Journal of Ophthalmology, v. 90, p. 337-41, 2006.

CHANDRA, S. R.; GRAGOUDAS, E. S.; FRIEDMAN, E.; VAN BUSKIRK, E. M.; KLEIN, M. L. Natural history of disciform degeneration of the macula. American Journal of Ophthalmology, v. 78, n. 4, p. 579-582, Oct. 1974.

CHAR D. H.; IRVINE A. I.; POSNER M. D.; QUIVEY J.; PHILLIPS T. L.; KROLL S. Randomized trial of radiation for age-related macular degeneration. American Journal of Ophthalmology, v. 127, p. 574-8, 1999.

CHEW E.Y.; CLEMONS T.; SANGIOVANNI J.P.; DANIS R.; DOMALPALLY A.; MCBEE W.; SPERDUTO R.; FERRIS F.L. AREDS 2 Research Group. The AgeRelated Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology. Nov; 119(11): 2282-9, 2012.

CHO E.; HANKINSON S.; WILLET W. C.; STAMPFER M. J.; SPIEGELMAN D.; SPEIZER F. E. Prospective study of alcohol consumption and the risk of age-related macular degeneration. Archives of Ophtalmology, v. 118, p. 681-8, 2000.

CHOPDAR A.; CHAKRAVARTHY U.; VERMA D. Age related macular degeneration. BMJ. Mar 1;326 (7387): 485-8. Review, 2003. CHUCAIR A. J.; ROTSTEIN N. P.; SANGIOVANNI J. P.; DURING A.; CHEW E. Y.; POLITI L. E. Lutein and zeaxanthin protect photoreceptors from apoptosis induced by oxidative stress: relation with docosahexaenoic acid. Investigative Ophthalmology & Visual Science, v. 48, p. 5168-5177, 2007. COBLEIGH M. A.; LANGMUIR V. K.; SLEDGE G. W.; MILLER K. D.; HANEY L.; NOVOTNY W. F.; REIMANN J. D.; VASSEL A. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Seminars in Oncology, v. 30, p. 117-24, 2003. COLE C.J.; CHARTERIS D.G. Cataract extraction after retinal detachment repair by vitrectomy: visual outcome and complications. Eye. 23(6): 1377–1381, 2009. CONGDON, N.; O’COLMAIN B.; KLAVER C. C.

W.; KLEIN R.; MUÑOZ B.; FRIELDMAN D. S. et al. Causes and prevalence of visual impairment among adults in the United States. Archives Ophthalmology, v. 122, n. 4, p. 477-485, Apr. 2004.

DAMIANO A. M.; BRESSLER N.; STRONG H. A.; PILSON L. A.; SNYDER C. F.; ADLER E. Y. The health related quality-of-life impact of late-stage age-related macular degeneration. Investigative Ophthalmology & Visual Science, v. 39, p. 602, 1998.

DAMICO D. J.; MASONSON H. N.; PATEL M.; ADAMIS A. P.; CUNNINGHAM JR E. T.; GUYER D. R.; KATZ B. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology, v. 113, p. 992-1001, 2006.

DAMICO, F. M. Angiogênese e doenças da retina. Arquivos Brasileiros de Oftalmologia, São Paulo, v. 70, n. 3, maio/jun. 2007. DASHTI N.; MCGWIN G.; OWSLEY C.; CURCIO C. A. Plasma apolipoproteins and risk for age related maculopathy. British Journal Ophthalmology, v. 90, n. 8, p. 1028- 1033, Aug. 2006.

DE GOWIN R. L.; LEWIS L. J.; HOAK J. C.; MUELLER A. L.; GIBSON D. P. Radiosensitivity of human endothelial cells in culture. Journal of Laboratory and Clinical Medicine, v. 84, p. 42-8, 1974. DING X, PATEL M, CHAN CC. Molecular pathology of age-related macular degeneration. Prog Retin Eye Res. 2009;28(1):1–18.

DUGEL P.U.; PETRARCA R.; BENNETT M.; et al. Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: Twelve-month safety and efficacy results. Ophthalmology. 119(7): 1425–1431, 2012.

DUGEL P.U.; BEBCHUK J.D.; NAU J. et al. CABERNET Study Group Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial. Ophthalmology 120(2):317–327, 2013.

DUGEL P.U.; JAFFE G.J.; SALLSTIG P.; WARBURTON J.; WEICHSELBERGER A.; WIELAND M.; SINGERMAN L. Brolucizumabe Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. Ophthalmology Sep;124(9):1296-1304, 2017.

DUNAIEF J. L.; DENTCHEV T.; YING G. S. The role of apoptose in age-related macular degeneration. Archives of Ophtalmology, v. 120, p. 1435-42, 2002.

EANDI C. M.; GIANSANTI F.; VIRGILI G. Macular translocation for neovascular age-related macular degeneration. Cochrane database of systematic reviews (Online), 2008.

EDINGTON M.; CONNOLLY J.; CHONG N.V. Pharmacokinetics of intravitreal antiVEGF drugs in vitrectomized eyes versus non-vitrectomized eyes. Expert Opin Drug Metab Toxicol. Dec;13(12): 1217-1224, 2017.

EDWARDS A. O.; RITTER R.; ABEL K. J.; MANNING A.; PANHUYSEN C.; FARRER L. A. Complement factor H polymorphism and age-related macular degeneration. Science, v. 308, p. 421-4, 2005.

EHRLICH R.; KHERADIYA N. S.; WINSTON D. M.; MOORE D. B.; WIROSTKO B.; HARRYS A. Age-related ocular vascular changes. Graefes Archive for Clinical and Experimental Ophthalmology, v. 247, n. 5, p. 583-591, May 2009.

EISSNER G.; KOHLHUBER F.; GRELL M.; UEFFING M.; SCHEURICH P.; HIEKE A.; MULTHOFF G.; BORNKAMM G. W.; HOLLER E. Critical involvement of transmembrane tumor necrosis factor-alpha in endothelial programmed cell death mediated by ionizing radiation and bacterial endotoxin. Blood Journal, v. 86, p. 4184- 93, 1995.

EMAMI B.; LYMAN J.; BROWN A.; et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 21(1):109–122, 1991.

ENGLANDER M.; KAISER P.K. Combination therapy for the treatment of neovascular age-related macular degeneration. Curr Opin Ophthalmol. 24(3): 233–238, 2013. ERGUN E.; STUR M. TTT and CNV. British Journal of Ophthalmology, v. 85. p.1013, 2001.

FARAH M.E. et al. Degeneração macular relacionada à idade: modalidades terapêuticas. Arq. Bras. Oftalmol. São Paulo, v.64, n.6, nov. 2001.

FARAH M.E.; CARDILLO J.A.; LUZARDO A.C.; CALUCCI D.; WILLIAMS G.A.; COSTA R.A. Indocyanine green mediated photothrombosis for the management of predominantly classic choroidal neovascularization caused by age related macular degeneration. Br J Ophthalmol. v. 88, n. 8, p. 1055-9, Ago. 2004.

FERRARA N.; DAVIS-SMYTH T. The biology of vascular endothelial growth factor. Endocr Rev. 18: 4–25, 1997.

HART P. M.; ARCHER D. B.; CHAKRAVARTHY U. Asymmetry of disciform scarring in bilateral disease when one eye is treated with radiotherapy. British Journal of Ophthalmology, v. 79, p. 562-8, 1995. HAYASHI K.; LAEY J. J. Indocyanine green angiography of choroidal neovascular membranes. Ophthalmologica, v. 190, p.30-39, 1985.

HAYEK S.; SCHERRER M.; BARTHELMES D.; FLEISCHHAUER J. C.; KURZLEVIN M. M.; MENGHINI M.; HELBIG H.; SUTTER F. K. First clinical experience with anecortave acetate (Retaane). Klin Monbl Augenheilkd, v. 224, p. 279-281, 2007.

HEIER J.S.; BROWN D.M.; CHONG V.; KOROBELNIK J.F.; et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 119: 2537–48, 2012.

HOCHHEIMER B. F.; SPRING S. Angiography of the retina with indocyanine green. Archives of Ophthalmology, v. 86, p. 564-565, 1971.

HOELLER U.; FUISTING B.; SCHWARTZ R.; ROEPER B.; RICHARD G.; ALBERTI W. Results of radiotherapy of subfoveal neovascularization with 16 and 20 Gy. Eye, v.19, p.1151-6, 2005.

HOLZ F.G. et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN Study.Ophthalmology. 2011; 118 (4): 663-671.

HOSOI Y.; SAKAMOTO K. Suppressive effect of low dose total body irradiation on lung metastasis: dose dependency and effective period. Radiotherapy & Oncology, v. 26, p. 177-9, 1993. HURWITZ H. I. New agents in colon cancer. Clinical Advances in Hematology and Oncology Journal, v. 1, p. 404-5, 2003.

IVANOV V.N.; ZHOU H.; GHANDHI S.A.; KARASIC T.B.; YAGHOUBIAN B.; AMUNDSON S.A. Radiation-induced bystander signaling pathways in human fibroblasts: a role for interleukin-33 in the signal transmission. Cell Signal. 22(7):1076–1087, 2010. JAAKKOLA A.; IMMONEN I. Radiotherapy in age-related macular degeneration. Duodecim Medical Publications, v. 114, p. 275-8, 1998. JACKSON T.L.; DESAI R.; SIMPSON A.; NEFFENDORF J.E.; PETRARCA R.; SMITH K.; WITTES J.; LEWIS C.; MEMBREY L.; HAYNES R.; COSTEN M.; STEEL D.H.; MULDREW A.; CHAKRAVARTHY U. Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration (MERLOT): A Phase 3 Randomized Controlled Trial. Ophthalmology. Jun;123(6): 1287-96, 2016. JACOB J.; BRIÉ H.; LEYS A.; LEVECQ L.; MERGAERTS F.; DENHAERYNCK K.; VANCAYZEELE S.; VAN CRAEYVELD E.; ABRAHAM I.; MACDONALD K. Six-year outcomes in neovascular age-related macular degeneration with ranibizumab. Int J Ophthalmol. Jan 18;10(1):81-90, 2017.

JAISSLE G.B.; SZURMAN P.; BARTZ-SCHMIDT K.U. Recommendation for the implementation of intravitreal injections / statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA). Klin Monbl Augenheilkd. May;222(5):390-5. German, 2005.

JAMPOL L.M. Oxygen therapy and intraocular oxygenation. Trans Am Ophthalmol Soc. 85:407–437, 1987. JONAS J. B.; DEGENRING R. F.; KREISSIG I.; FRIEDEMANN T.; AKKOYUN, I. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study. Eye (Lond), v. 19, p. 163- 170, 2005a.

JONAS J. B.; DEGENRING R. F.; KREISSIG I. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Progress in Retinal and Eye Research on ScienceDirect, v. 24, p. 587-611, 2005b.

KAWASAKI R.; YASUDA M.; SONG S.J.; et al. The prevalence of age-related macular degeneration in Asians: a systematic review and metaanalysis. Ophthalmology. 117(5): 921–927, 2010.

KHAN J. C.; SHAHID H.; THURLBY D. A.; BRADLEY M.; CLAYTON D. G.; MOORE A. T.; BIRD A. C.; YATES J. R. Age related macular degeneration and sun exposure, iris colour, and skin sensitivity to sunlight. British Journal of Ophthalmology, v. 90, p. 29–32, 2006a.




DOI: https://doi.org/10.34117/bjdv6n9-062

Refbacks

  • There are currently no refbacks.